Obesity and Obesity-related Medical Conditions
Conditions
Keywords
Mediterranean lunch boxes, Obesity, Diabetes
Brief summary
The study aims to explore the effects of a tailored nutritional intervention for maintaining (normal-weight subjects) or reducing (overweight or obese subjects) body weight. In a subgroup of patients with prediabetes/T2DM, the effect of the nutritional intervention by Mediterranean lunch boxes developed in the PRIMA project on gluco-lipid homeostasis will be also evaluated. Secondary objectives are to evaluate the nutritional and functional benefits of the intervention strategies on pathogenetic factors affecting metabolic and pro-inflammatory status and intestinal permeability.
Detailed description
Protocol summary The study aims to explore the effects of a tailored nutritional intervention for maintaining (normal-weight subjects) or reducing (overweight or obese subjects) body weight. In a subgroup of patients with prediabetes/T2DM, the effect of the nutritional intervention by Mediterranean lunch boxes developed in the PRIMA project on gluco-lipid homeostasis will be also evaluated. Secondary objectives are to evaluate the nutritional and functional benefits of the intervention strategies on pathogenetic factors affecting metabolic and pro-inflammatory status and intestinal permeability. Patients All enrolled participants (n=450, age 25-65) will undergo, following written informed consent, a 12-weeks, controlled, randomized, multicenter clinical study with multiple arms conducted on normal weight, overweight or obese subjects with or without prediabetes or other metabolic risk factors in Italy and Lebanon. Study design Participants will be assigned to the healthy group (HG, n= 150) or to the dysmetabolic group (DG, n=300) according to a previous clinical assessment. The two groups will be comparable for age/gender composition. In each group, subjects will be randomized to continue the ongoing diet (controls) or to receive one of the lunch boxes developed in the project (L-MedFood or F-MedFood, \ 600 kcal) 3-times/week during 12 weeks (treatment). In the treated groups, healthy subjects will receive the L-MedFood lunch box, the overweight/obese subjects, with or without prediabetes/T2DM, will receive the F-MedFood Box. The consumption of lunch boxes will be associated, in all enrolled subjects, with the use of iMFood, an interactive and easy-to-understand APP developed in this project and fulfilling the goal of a new Agro-Food Value Chain solution, to enable the transition to healthy and sustainable dietary behavior. Groups The different arms of the study will be as follows: * Group 1: Lean, ongoing diet (n=40); * Group 2: Lean, B4HT (n= 40); * Group 3: OW/OB without prediabetes/T2DM ongoing diet (n=40); * Group 4: OW/OB without prediabetes/T2DM, B4HT (n= 40); * Group 5: OW/OB, with prediabetes/T2DM, ongoing diet (n=40); * Group 6: OW/OB with prediabetes/T2DM, B4HT (n= 40). Participants will have follow-up phone/physical visits every third week (4 visits). These subjects will receive Fat-Dysmetabolic Box (3-times/week) and APP iMFood with standard-of-care pharmacological treatments. Duration The study is planned to last 12 weeks. Outputs In all arms of the study, the primary outcomes are weight loss and satisfaction index. Secondary outcomes include changes in gluco-lipid homeostasis and in visceral and liver fat quantitative ultrasonography, adherence to Mediterranean diet (assessed and monitored by the validated score MEDI-LITE). Exploratory analyses will include analyses of inflammatory status, intestinal permeability as assessed by oral quadruple test ingestion, gut microbiota profile and metabolomic analysis. Cause-and-effect relationships between B4HT and risk reduction and decrease in obesity rate and other metabolic abnormalities.
Interventions
lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, \ 600 kcal)
Sponsors
Study design
Eligibility
Inclusion criteria
* Subjects able to provide Informed Consent * Age over 18 years
Exclusion criteria
* Lack of informed consent * Pregnancy * Chemotherapy * Participation in other research protocols.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight (Kg) | From enrollment to the end of treatment at 12 weeks | The primary outcome isweight loss |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting glucose | From enrollment to the end of treatment at 12 weeks | Change in glycemic profile |
| Lipid profile (TC, TG, LDL, HDL) | From enrollment to the end of treatment at 12 weeks | Change in Lipid profile |
| Liver enzymes | From enrollment to the end of treatment at 12 weeks | Change in AST, ALT, and GGT |
| Abdominal fat storage | From enrollment to the end of treatment at 12 weeks | Change in abdominal fat depostion |
| Liver steatosis | From enrollment to the end of treatment at 12 weeks | Assesment of liver fat accumulation |
Other
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory markers | At baseline and at the end of treatment (12 weeks) | Assessment of serum inflammatory markers such as Interleukins and cytokines |
| Gut Microbiota | At baseline and at the end of treatment (12 weeks) | Assessment of fecal gut microbiota composition |
Countries
Italy